SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Merck Reports Pimicotinib Tumor Response at Two Years in Phase 3 TGCT Study

Merck reported a tumor response at two years in its phase 3 study of pimicotinib for TGCT.

MERCK

Related stories